本文整理自“‘工业互联网+生物制药’落地场景及经验分享”CIO直播活动高端对话，太极集团CIO杨靖、龙凤堂中药有限公司数字化负责人蒋军分享了企业工业互联网应用场景及成果，并对企业未来数字化规划作了详细解读。
一、企业工业互联网落地应用的典型场景与经验
太极集团杨靖： 从企业管理者的角度 来看工业互联网的应用场景怎么去打造，聚焦在大数据分析和智能决策分析平台的建设上，外部因素是国家的发展规划，行业发展规划以及行业监管和市场竞争的要求。从内部因素考虑，工业互联网平台必须要具备几个能力：
① 管控能力，这是企业的一大痛点，所以需要通过大数据平台建设来提高企业的管控能力；数字化转型网szhzxw.cn
② 运营能力；
③ 创新能力；数字化转型网szhzxw.cn
而对于数据应用场景的打造，需要能够实现企业的数字产业化，给企业内外的一些相关企业赋能。按照国家的要求，大型企业或者头部企业，必须做一些主导产业链平台化的建设，实现未来的双轮驱动，包括：传统产业的高效运营和能力提升；具备打造数字产业化的能力。所以，在数字场景打造的过程中，最大的挑战来自于高层的认知。数字化转型网szhzxw.cn
扬子江药业集团龙凤堂中药有限公司数字化负责人蒋军： 龙凤堂工业互联网平台今年刚刚获得省级工业互联网示范工程项目（标杆工厂类）。现在中药面临的行业难题是中药药材的稳定性，同时也面临着生存的空间压缩，利润下降的挑战。这就为企业提出了提升产品质量、降低成本、提高资产利用率的更高要求。数字化转型网szhzxw.cn
针对中药制造至今未形成标准化的问题，从2013年至今，龙凤堂在不断的摸索，并建设以DCS+MES+TIMMS为核心的智能制造平台，通过采集底层业务数据搭建管理驾驶舱，希望通过大数据分析平台为企业决策提供强有力的支撑。同时，龙凤堂在2019年摸索自建了一套中药种植溯源系统，已完全打通上下游产业链，后期通过分析种植数据实现中草药种植的标准化。
戴尔科技集团企业级云计算及超融合架构师仲从俊： 现在，生物制药公司对于数据重要性的认知的程度越来越高，戴尔科技不单单是一家传统IT公司，对于整个数据处理链条有全方位的解决方案，在生物制药行业的应用也非常广泛。戴尔科技可以帮助用户构建虚拟化，包括私有云的平台。
目前，在生物制药行业，戴尔最大的超融合解决方案客户部署规模已经接近300个节点，其基础架构平台分为三部分：虚拟化的平台、大数据平以及数据保护。通过戴尔科技给用户提供的这三个解决方案的组合，基本上可以帮助企业应对整个数据链条的处理需求。同时，能够非常有效的应对合规性要求。最重要的是用户的售后服务可以获得由戴尔科技提供的单一技术服务支持，整体的用户体验是非常好的。
现场问答：XPU需要对软件进行迁移/二次开发吗？生物制药领域，英特尔跟其他产品相比的优势是什么？数字化转型网szhzxw.cn
英特尔医疗及生命科学行业技术总监吴一鸣：XPU在2024年会推向市场，是 一个从架构层面做了一个颠覆性的产品。目前的愿景就是在CPU、GPU上随着芯片创新给客户带来迁移成本的降低。它的目的是帮助用户把现有的平台功能通过软件的方式实现自动化的迁移，这个迁移的成本是非常低的。等到2024年新架构发布时，无论是迁移成本，还是整个软件的生态会非常的成熟。www.szhzxw.cn数字化转型网szhzxw.cn
在生物制药行业行业，英特尔与其他的友商有一个最大的区别。首先是自身立足之本是芯片的研发，目前也是相对最全的。除了大家比较熟悉的像桌面电脑用到的酷睿处理器，数据中心最强的处理器GPU等等。另外，对于制药企业来讲，创新药的研发其核心竞争力的体现，而在过去几年研发的成本非常高。英特尔在打造的一个混合架构方案，同时研究院在做冯诺伊曼的计算框架的产品，像神经元的以太芯片实现了AI技术制药行业的应用，可以大幅度降低能耗，降低管理成本。目前，这款新型产品和国内非常多的头部制药企业在自动化方面做了一些探索，包括项目的落地。
所以行业的生态建设是英特尔除了立足之本的芯片研发以外，非常重视的一块投入，这是英特尔和传统芯片企业最大的不同。数字化转型网szhzxw.cn
二、未来工业互联网应用/数字化的规划
太极集团杨靖： 第一，要打造企业高效的管控能力和运营能力，同时还要给企业提供一个新发展模式，做平台化的企业。基于这个规划我们会做几方面的工作：
搭建一个云底座。提供数字化转型的基础设施，赋能于企业的数字化建设。
两个体系的建设。数字化治理体系和网络安全体系，为数字化转型保驾护航。
构建三个平台：集中的数字化管控平台；产业数字化运营平台；企业的产业数字化服务平台
第二，要做全域数字化营销。整合企业所有的渠道资源，按照全域数字营销的角度重新对组织进行划分。
第三，打造N个应用场景。应用场景要像乐高积木一样，由点到线，由线到面这样去推进。
具体实施方面：2022年~2023年，企业要完成顶层设计，找准定位；2022年~2024年，整合企业内外部资源。研究各板块数字化转型的关键环节、解决方案及实施路径。
第四，集成融合、通态协同。依托工业互联网标识解析平台，基于数据中台、业务中台的技术架构，打通研发、种植、生产、营销等环节。构建跨组织、跨行业的全产业链数字平台，形成集团的数字化核心能力。数字化转型网szhzxw.cn
扬子江药业集团龙凤堂中药有限公司数字化负责人蒋军： 首先，标准化种植是公司未来努力发展的一个重要方向，中药种植溯源系统沿用了国家二级节点解析的思路，目前我们能追踪到前端的种植环节，从药材的种植、施肥、采收、运输均能查询。
其次，我们是集团分公司经营的模式，生产和研发体系是独立的，如何融合打通业务间的数据是接下来一个重要的工作，利用智能制造积累的数据围绕如何优化生产工艺和提高研发效率开展。数字化转型网szhzxw.cn
最后，数据治理也是我们重点工作内容之一，围绕业务数据化，数据业务化，夯实数字化转型的基础，但数字化人才的缺乏是我们当下面临的主要挑战。
在中药大健康产业转型方面，龙凤堂打造医、药、养、健、游五位一体的中药健康产业集群，尝试向工业旅游2C方向发展。此外，结合创新技术对传统中医诊疗技术进行创新，比如通过AI问诊为一些病患进行诊断。数字化转型网szhzxw.cn
中药讲究的是“治未病”，旨病患在未生病前就对身体机能进行调理。但这个基理很难讲清楚，所以也是中药走向国际化一个最大的挑战。通过智能化制药工艺，融合生产大数据与临床大数据，将中药说清楚、弄明白，生产出疗效明确、机制清晰、安全可靠、质量可控的优质中药产品。www.szhzxw.cn数字化转型网szhzxw.cn
戴尔科技集团企业级云计算及超融合架构师仲从俊： 中国的生物制药企业，在走向全球市场以及数字化转型的过程中，产业链会越来越丰富，系统越来越多，会形成一个个的孤岛。在这个背景下，企业普遍采用的方式是搭建新的数据中心进行数据整合及应用，一般会采用横向扩展的架构，而超融合就是典型的横向扩展架构，这也是一个非常好的值得大家参考的一个方向 。
工业互联网落地应用，一方面为企业数字化建设贡献了更多的路径和空间，同时，也为企业的数字化转型提供了方向。在这个过程中，落地场景、能效等问题在各个行业仍处于不断的探索当中。而快速发展的生物制药行业于工业互联网落地实践的成果，无疑对于行业的数字化加速，以及跨行业的工业互联网应用都有良好的参考价值。数字化转型网szhzxw.cn
翻译：数字化转型网szhzxw.cn
In this paper, the CIO of Taiji Group Yang Jing, the CIO of Longfengtang Traditional Chinese Medicine Co., LTD., Jiang Jun, the digital director, shared the enterprise industrial Internet application scenarios and results, and made a detailed interpretation of the enterprise’s future digital planning.
Typical scenarios and experience of enterprise industrial Internet landing application数字化转型网szhzxw.cn
Yang Jing, Taiji Group: From the perspective of enterprise managers, how to build the application scene of the industrial Internet, focusing on the construction of big data analysis and intelligent decision analysis platform, external factors are the national development plan, industry development plan, industry supervision and market competition requirements. From internal factors, the industrial Internet platform must have several capabilities:
(1) Management and control ability, which is a big pain point for enterprises, so it is necessary to improve the management and control ability of enterprises through the construction of big data platform;
(2) Operation ability;
(3) innovation ability;
As for the creation of data application scenarios, it is necessary to realize the digital industrialization of enterprises and empower some relevant enterprises inside and outside enterprises. According to the requirements of the state, large enterprises or leading enterprises must do some leading industry chain platform construction, to achieve the future two-wheel drive, including: efficient operation of traditional industries and capacity improvement; Have the ability to create digital industrialization. So the biggest challenge in building a digital scene is perception at the top.
Jiang Jun, digital Director of Longfengtang Traditional Chinese Medicine Co., LTD., Yangzijiang Pharmaceutical Group:
Longfengtang Industrial Internet platform just won the provincial Industrial Internet Demonstration project this year (benchmarking factory). At present, the traditional Chinese medicine industry is facing the problem of stability of traditional Chinese medicine, but also facing the challenge of compressed survival space and declining profit. This puts forward higher requirements for enterprises to improve product quality, reduce costs and improve asset utilization.
Since 2013, Longfengtang has been exploring and building an intelligent manufacturing platform with DCS+MES+TIMMS as the core. By collecting low-level business data, Longfengtang has built a management cockpit, hoping to provide strong support for corporate decision-making through big data analysis platform. Meanwhile, Longfengtang explored and built a TCM planting traceability system in 2019, which has completely connected the upstream and downstream industrial chain, and realized the standardization of TCM planting by analyzing planting data in the later stage.
Zhong Congjun, Architect of enterprise-level cloud computing and hyper-convergence of Dell Technology Group: www.szhzxw.cn
Now, biopharmaceutical companies are more and more aware of the importance of data. Dell Technology is not only a traditional IT company. But also has a comprehensive solution for the whole data processing chain. And has a wide range of applications in the biopharmaceutical industry. Dell Technologies can help users build virtualization platforms, including private clouds.数字化转型网szhzxw.cn
Currently, in the biopharmaceutical industry, Dell’s largest hyperconverged solution customer deployment scale has reached nearly 300 nodes. And its infrastructure platform is divided into three parts: virtualization platform, big data platform and data protection. The combination of these three solutions provided by Dell Technologies to users basically helps enterprises cope with the processing needs of the entire data chain. At the same time, it can deal with compliance requirements very effectively. The most important thing is that users can get a single technical service support provided by Dell Technology. The overall user experience is very good.
Q&a: Does XPU Require software migration/secondary development? What is Intel’s advantage over other products in biopharmaceuticals?
Yiming Wu, Intel Medical and Life Sciences Industry technical Director:
XPU will be launched in 2024. It is a disruptive product from an architectural level. The current vision is to reduce migration costs for customers along with chip innovation in CPU and GPU. Its purpose is to help users to automate the migration of existing platform functions by means of software at a very low cost. By the time the new architecture is released in 2024. Both the migration costs and the overall software ecology will be very mature.数字化转型网szhzxw.cn
There is one big difference between Intel and its friends in the biopharmaceutical industry. First of all, it is based on its own chip research and development, which is relatively complete at present. In addition to the familiar core processors used in desktop computers, the most powerful processors in data centers, Gpus, and so on. In addition, for pharmaceutical companies, the research and development of innovative drugs is the embodiment of their core competitiveness, but the cost of research and development in the past few years is very high.
Intel is building a hybrid architecture scheme, while the research institute is doing von Neumann’s computing framework products, such as neuronal Ethernet chip to realize the application of AI technology in the pharmaceutical industry, which can greatly reduce energy consumption and management costs. At present, this new product and a lot of domestic head pharmaceutical enterprises in the automation aspect to do some exploration, including the project landing.
Therefore, the ecological construction of the industry is Intel in addition to the fundamental chip research and development, attaches great importance to a piece of investment, which is the biggest difference between Intel and traditional chip enterprises.
Planning of future industrial Internet application/digitization
Yang Jing of Taiji Group: www.szhzxw.cn数字化转型网szhzxw.cn数字化转型网szhzxw.cn
First, it is necessary to build efficient management and control ability and operation ability of enterprises. At the same time, it is also necessary to provide enterprises with a new development mode and become a platform-based enterprise. Based on this plan, we will do the following work:
Build a cloud base. Provide the infrastructure of digital transformation, enabling the digital construction of enterprises.
The construction of two systems. The digital governance system and cyber security system will escort the digital transformation.
Construct three platforms: centralized digital management and control platform; Industrial digital operation platform; Enterprise’s industrial digital service platform
Second, to do the whole digital marketing. Integrate all the channel resources of the enterprise, and re-divide the organization according to the perspective of global digital marketing.
Third, create N application scenarios. The application scene should move from point to line and from line to surface like Lego.
Specific implementation: from 2022 to 2023, the enterprise should complete the top-level design and find the right positioning; From 2022 to 2024, integrate internal and external resources of the enterprise. Study the key links, solutions and implementation paths of digital transformation in each sector.数字化转型网szhzxw.cn
Fourth, integration and integration, on-state coordination. Relying on the industrial Internet logo analysis platform and based on the technical framework of data center and business center, it can open up the links of research and development, planting, production and marketing. Build a digital platform of the whole industrial chain across organizations and industries, and form the core digital capabilities of the Group.
Jiang Jun, digital director of Longfengtang Traditional Chinese Medicine Co., LTD., Yangzijiang Pharmaceutical Group:
First of all, standardized planting is an important direction for the company’s future development. The traditional Chinese medicine planting traceability system follows the national secondary node analysis idea.
Secondly, we operate as a branch of the group, and the production and research and development systems are independent. The next important task is how to integrate and get through the data between businesses. We will use the accumulated data of intelligent manufacturing to focus on how to optimize the production process and improve the efficiency of research and development.数字化转型网szhzxw.cn
Finally, data governance is also one of our key work contents. Centering on business digitization and data business, we can consolidate the foundation of digital transformation. However, the shortage of digital talents is the main challenge we are facing at present.
In terms of the transformation of the TCM health industry, Longfengtang has built a TCM health industry cluster integrating medicine, medicine, nutrition, health and tourism, trying to develop towards the 2C direction of industrial tourism. In addition, traditional Chinese medicine diagnosis and treatment techniques will be innovated by combining innovative technologies, such as diagnosing some patients through AI consultation.
Traditional Chinese medicine focuses on the “treatment of disease”, aiming at patients to regulate their body functions before they get sick. But this rationale is difficult to explain, which is one of the biggest challenges to the internationalization of TCM. Through the intelligent pharmaceutical process and the integration of production big data and clinical big data, TCM can be clarified and clarified, and high-quality TCM products with clear curative effect, clear mechanism, safe and reliable, and controllable quality can be produced.
Zhong Congjun, architect of enterprise-level cloud computing and hyper-convergence of Dell Technology Group:
In the process of entering the global market and digital transformation, China’s biopharmaceutical enterprises will become more and more rich industrial chain, more and more systems, and will form islands one by one. In this context, enterprises generally adopt the way to build new data centers for data integration and application, and generally adopt the horizontal extension architecture, and hyperfusion is a typical horizontal extension architecture, which is also a very good direction worthy of reference.数字化转型网szhzxw.cn
The practical application of industrial Internet, on the one hand, contributes more paths and space for the digital construction of enterprises, at the same time, also provides the direction for the digital transformation of enterprises. In this process, landing scene, energy efficiency and other issues are still under constant exploration in various industries. The rapid development of biopharmaceutical industry in industrial Internet practice results, no doubt for the industry’s digital acceleration, as well as cross-industry industrial Internet applications have good reference value.
本文由数字化转型网转载，可以关注数字化转型网公众号
本文由数字化转型网（www.szhzxw.cn）转载而成，来源：ENI经济和信息化网；编辑/翻译：数字化转型网宁檬树。
免责声明: 本网站(http://www.szhzxw.cn/)内容主要来自原创、合作媒体供稿和第三方投稿，凡在本网站出现的信息，均仅供参考。本网站将尽力确保所提供信息的准确性及可靠性，但不保证有关资料的准确性及可靠性，读者在使用前请进一步核实，并对任何自主决定的行为负责。本网站对有关资料所引致的错误、不确或遗漏，概不负任何法律责任。
本网站刊载的所有内容(包括但不仅限文字、图片、LOGO、音频、视频、软件、程序等) 版权归原作者所有。任何单位或个人认为本网站中的内容可能涉嫌侵犯其知识产权或存在不实内容时，请及时通知本站，予以删除。
